MicroRNA expression in cytogenetically normal acute myeloid leukemia

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNAs are increasingly recognized for their role in cancer development.
• The specific involvement of microRNAs in acute myeloid leukemia (AML) remains largely unexplored.

Purpose of the Study:

• To investigate the association between microRNA expression and clinical outcomes in adult patients with high-risk, cytogenetically normal AML.
• To identify a microRNA signature predictive of event-free survival in this patient cohort.

Main Methods:

• MicroRNA expression profiling was performed on leukemia cells from 119 adult patients (<60 years) with cytogenetically normal AML and high-risk molecular features (FLT3-ITD and/or NPM1 mutations).
• A microRNA signature associated with event-free survival was identified in a training set (n=64) and validated in an independent set (n=55).
• Gene-expression analysis was used to correlate microRNA expression with predicted target genes involved in innate immunity pathways.

Main Results:

• Twelve microRNA probes, including five from the microRNA-181 family, were significantly associated with event-free survival in the training group.
• A derived microRNA summary value was inversely associated with event-free survival in the validation group (P=0.03) and remained significant in multivariable analysis.
• Expression of the microRNA-181 family inversely correlated with predicted target genes in innate immunity pathways, including toll-like receptors and interleukin-1beta.

Conclusions:

• A distinct microRNA signature is associated with clinical outcomes in molecularly defined, high-risk, cytogenetically normal AML.
• This microRNA signature is linked to target genes involved in specific innate immunity pathways, suggesting a potential role in AML pathogenesis and prognosis.